The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection
Open accessAbstract
COVID-19, is a disease resulting from the SARS-CoV-2 global pandemic. Due to the current global emergency and the length of time required to develop specific antiviral agent(s) and a vaccine for SARS-CoV-2, the world health organization (WHO) adopted the strategy of repurposing existing medications to treat COVID-19. Iron oxide nanoparticles (IONPs) were previously approved by the US food and drug administration (FDA) for anemia treatment and studies have also demonstrated its antiviral activity in vitro. Therefore, we performed a docking study to explore the interaction of IONPs (Fe2O3 and Fe3O4) with the spike protein receptor binding domain (S1-RBD) of SARS-CoV-2 that is required for virus attachment to the host cell receptors. A similar docking analysis was also performed with hepatitis C virus (HCV) glycoproteins E1 and E2. These studies revealed that both Fe2O3 and Fe3O4 interacted efficiently with the SARS-CoV-2 S1-RBD and to HCV glycoproteins, E1 and E2. Fe3O4 formed a more stable complex with S1-RBD whereas Fe2O3 favored HCV E1 and E2. These interactions of IONPs are expected to be associated with viral proteins conformational changes and hence, viral inactivation. Therefore, we recommend FDA-approved-IONPs to proceed for COVID-19 treatment clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents.
Kampf, G., Todt, D., Pfaender, S., & Steinmann, E. (2020) · Journal of Hospital Infection · doi:10.1016/j.jhin.2020.01.022 · Cited by 3,796
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease
Coyne, D. W. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903224998 · Cited by 95
Cited by
Magnetic nanoparticles in biomedical applications: A review
Materón, E. M., Miyazaki, C. M., Carr, O., Joshi, N., Picciani, P. H. S., Dalmaschio, C. J., Davis, F., & Shimizu, F. M. (2021) · Applied Surface Science Advances · doi:10.1016/j.apsadv.2021.100163 · Cited by 456
Recent advances in green synthesized nanoparticles: from production to application
kazemi, S., Hosseingholian, A., Gohari, S. D., Feirahi, F., Moammeri, F., Mesbahian, G., Moghaddam, Z. S., & Ren, Q. (2023) · Materials Today Sustainability · doi:10.1016/j.mtsust.2023.100500 · Cited by 341
Fritea, L., Banica, F., Costea, T., Moldovan, L., Dobjanschi, L., Muresan, M., & Cavalu, S. (2021) · Materials · doi:10.3390/ma14216319 · Cited by 311
Burlec, A. F., Corciova, A., Boev, M., Batir-Marin, D., Mircea, C., Cioanca, O., Danila, G., Danila, M., Bucur, A. F., & Hancianu, M. (2023) · Pharmaceuticals · doi:10.3390/ph16101410 · Cited by 295
Conklin, B., Conley, B. M., Hou, Y., Chen, M., & Lee, K.-B. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114636 · Cited by 45
Metadata
- Authors
- Abo-zeid, Y., Ismail, N. S. M., McLean, G. R., & Hamdy, N. M.
- Venue
- European Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 153
- Pages
- 105465
- ISSN
- 0928-0987 (ISSN-L)
- OpenAlex
- W3041042540
- Cited by
- 238
- References
- 3
- FWCI
- 5.58
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.